Cargando…

Real‐world experience of carfilzomib‐associated cardiovascular adverse events: SEER‐Medicare data set analysis

Carfilzomib was approved for the treatment of multiple myeloma in 2012 and since then there have been concerns for cardiovascular toxicity from its use. With this study, we aim to further study the hazards and underlying risk factors for cardiovascular adverse events associated with carfilzomib. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bishnoi, Rohit, Xie, Zhigang, Shah, Chintan, Bian, Jiang, Murthy, Hemant S., Wingard, John R., Farhadfar, Nosha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826471/ https://www.ncbi.nlm.nih.gov/pubmed/33169938 http://dx.doi.org/10.1002/cam4.3568

Ejemplares similares

Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study
por: Bishnoi, Rohit, et al.
Publicado: (2019)

Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials
por: Shah, Chintan, et al.
Publicado: (2018)

Racial Disparities in Breast Cancer Treatments and Adverse Events in the SEER-Medicare Data
por: Wieder, Robert, et al.
Publicado: (2023)

Overview of the SEER—Medicare Health Outcomes Survey Linked Dataset
por: Ambs, Anita, et al.
Publicado: (2008)

Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real‐world evidence from the medicare population
por: Goyal, Ravi K., et al.
Publicado: (2021)

Overview of the progress on haploidentical hematopoietic transplantation
por: Farhadfar, Nosha, et al.
Publicado: (2016)

Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States
por: Zhai, Yinghong, et al.
Publicado: (2021)

Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER‐Medicare investigation
por: Beebe‐Dimmer, Jennifer L., et al.
Publicado: (2019)

Associations between initiating antihypertensive regimens on stage I–III colorectal cancer outcomes: A Medicare SEER cohort analysis
por: Balkrishnan, Rajesh, et al.
Publicado: (2021)

Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER‐medicare analysis
por: Ailawadhi, Sikander, et al.
Publicado: (2017)

Risk factors for venous thromboembolism in metastatic colorectal cancer with contemporary treatment: A SEER‐Medicare analysis
por: Ades, Steven, et al.
Publicado: (2022)

Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023
por: Farhadfar, Nosha, et al.
Publicado: (2021)

Survival outcomes in an older US population with advanced melanoma and central nervous system metastases: SEER‐Medicare analysis
por: Sadetsky, Natalia, et al.
Publicado: (2020)

Differences in cancer survival among white and black cancer patients by presence of diabetes mellitus: Estimations based on SEER‐Medicare‐linked data resource
por: Lam, Clara, et al.
Publicado: (2018)

Severity of comorbid conditions and early-stage breast cancer therapy: linked SEER-medicare data from 1993 to 2005
por: Yasmeen, Shagufta, et al.
Publicado: (2013)

Chemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: A SEER‐Medicare study
por: Shao, Changxia, et al.
Publicado: (2019)

Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis
por: Scarton, Lisa, et al.
Publicado: (2022)

Carfilzomib-induced Cardiotoxicity: An Analysis of the FDA Adverse Event Reporting System (FAERS)
por: Buck, Benjamin, et al.
Publicado: (2022)

Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front‐line regimens using the SEER‐Medicare data
por: Goto, Daisuke, et al.
Publicado: (2019)

Multiple oral squamous cell carcinoma 6 years after allogeneic stem cell transplantation complicated with chronic graft-versus-host disease: A case report
por: Katz, Joseph, et al.
Publicado: (2022)

Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods
por: Aly, Abdalla, et al.
Publicado: (2015)

Comparison of SEER Treatment Data With Medicare Claims
por: Noone, Anne-Michelle, et al.
Publicado: (2016)

Serious adverse events in African–American cancer patients with sickle cell trait and inherited haemoglobinopathies in a SEER-Medicare claims cohort
por: Hoag, Jessica R., et al.
Publicado: (2019)

Real‐World Clinical and Economic Outcomes in Selected Immune‐Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors
por: Zheng, Ying, et al.
Publicado: (2021)

Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia
por: Norkin, Maxim, et al.
Publicado: (2017)

Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study
por: Astarita, Anna, et al.
Publicado: (2023)

Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database
por: Beebe-Dimmer, Jennifer L., et al.
Publicado: (2018)

Impact of serious mental illness on the treatment and mortality of older patients with locoregional high‐grade (nonmetastatic) prostate cancer: retrospective cohort analysis of 49 985 SEER‐Medicare patients diagnosed between 2006 and 2013
por: Fried, Dennis A., et al.
Publicado: (2019)

Correction to: Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database
por: Beebe-Dimmer, Jennifer L., et al.
Publicado: (2018)

Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib
por: Harvey, R Donald
Publicado: (2014)

Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events
por: Tsakiri, Eleni N., et al.
Publicado: (2017)

Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis
por: Onda, Yoshiyuki, et al.
Publicado: (2022)

Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer
por: Shao, Jun, et al.
Publicado: (2020)

Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction
por: Astarita, Anna, et al.
Publicado: (2021)

Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience
por: Mingrone, Giulia, et al.
Publicado: (2023)

Racial disparities in pancreatic neuroendocrine tumors survival: a SEER study
por: Zhou, Huaqiang, et al.
Publicado: (2017)

Hepatocellular Carcinoma Survival by Etiology: A SEER‐Medicare Database Analysis
por: Brar, Gagandeep, et al.
Publicado: (2020)

Opportunities for Personalizing Colorectal Cancer Care: An Analysis of SEER-Medicare Data
por: Rivers, Zachary T., et al.
Publicado: (2022)

Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy
por: Bruno, Giulia, et al.
Publicado: (2019)

Neonates with cancer and causes of death; lessons from 615 cases in the SEER databases
por: Alfaar, Ahmad S., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9rqaje42v33p6fd26gjv4vbf1o